

Table S1: Cases of 'second hit' drug-associated severe cutaneous reactions following mRNA COVID-19 vaccination

Patient (reference)	'First hit' drug (<i>treatment duration before reaction</i>)	'Second hit' mRNA COVID-19 vaccination (<i>time until reaction</i>)	Reaction	Management and outcome
29 y.o. female (present case)	Penicillamine (10 days)	Pfizer- BioNTech (2 days)	Morbiliform eruption and SIRS	Prednisolone + topical betamethasone, resolution in 1 week
68 y.o. male (1)	Carbamazepine (33 days)	Pfizer- BioNTech (6 days)	DRESS, elevated liver transaminases	Prednisone, improved over 5 weeks
31 y.o. male (1)	Allopurinol (38 days)	Moderna (2 days)	DRESS, elevated liver transaminases	Prednisolone, improved over 6 weeks
71 y.o male (1)	Carbamazepine (58 days)	Pfizer-BioNTech (8 days)	DRESS, elevated liver transaminases + interstitial pneumonitis	Steroid pulse, improved within 3 days
62 y.o female (2)	Trimethoprim-Sulphamethoxazole (3 weeks), and prior ipilimumab/nivolumab	Pfizer- BioNTech (2 days)	Erythrodermic lichenoid dermatitis with mucosal and eye involvement	Intravenous methylprednisolone then prednisolone, improved over 2 weeks
67 y.o male (3)	Vildagliptin (10 years)	Non-specified mRNA vaccine, NR (5 weeks)	Bullous pemphigoid	Prednisolone + omalizumab, improved over 8 months
67 y.o male (4)	Vildagliptin (>1 year)	Pfizer- BioNTech (<i>timing NR</i>)	Bullous pemphigoid	Doxycycline, partial control at 1 month
84 y.o female (4)	Linagliptin (>1 year)	Pfizer- BioNTech (<i>timing NR</i>)	Bullous pemphigoid	Prednisolone, partial control at 1 month
86 y.o female (4)	Linagliptin (>1 year)	Pfizer- BioNTech (<i>timing NR</i>)	Bullous pemphigoid	Prednisolone, partial control at 1 month
75 y.o male (5)	Non-specified gliptin (<i>duration NR</i>)	Pfizer- BioNTech (2 days)	Bullous pemphigoid	Topical steroids, outcome NR

DRESS, drug reaction with eosinophilia and systemic symptoms; NR, not reported; SIRS, systemic inflammatory response syndrome; y.o., years old